Ignite Creation Date:
2025-12-25 @ 2:07 AM
Ignite Modification Date:
2025-12-26 @ 2:34 AM
Study NCT ID:
NCT05600660
Status:
RECRUITING
Last Update Posted:
2022-11-08
First Post:
2022-10-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-27
First Submit QC Date:
None
Study First Post Date:
2022-10-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-03
Last Update Post Date:
2022-11-08
Last Update Post Date Type:
ACTUAL